Cargando…
Can the use of long-acting injectable antipsychotic preparations be increased in routine clinical practice and the benefits realised?
BACKGROUND: The use of continuing antipsychotic medication is an established evidence-based strategy for preventing relapse in people with schizophrenia, but medication adherence is known to be suboptimal. Covert non-adherence can be eliminated by the use of long-acting injectable (LAI) formulations...
Autores principales: | Paton, Carol, Okocha, Chike I., Patel, Maxine X. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8854225/ https://www.ncbi.nlm.nih.gov/pubmed/35186261 http://dx.doi.org/10.1177/20451253211072347 |
Ejemplares similares
-
Attitudes of European physicians towards the use of long-acting injectable antipsychotics
por: Patel, Maxine X., et al.
Publicado: (2020) -
Clinical benefits and impact of early use of long‐acting injectable antipsychotics for schizophrenia
por: Stevens, Georgia L., et al.
Publicado: (2015) -
Clinical Benefit and Utility of Switching to Aripiprazole Once Monthly in Patients with Antipsychotic Polypharmacy or Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study
por: Pae, Chi-Un, et al.
Publicado: (2021) -
The pharmacological management of acute behavioural disturbance: Data from a clinical audit conducted in UK mental health services
por: Paton, Carol, et al.
Publicado: (2018) -
Physical health monitoring after rapid tranquillisation: clinical
practice in UK mental health services
por: Paton, Carol, et al.
Publicado: (2019)